Scholarlink

<p>We evaluated the therapeutic effect of psoralidin combined with cisplatin in a mouse model of breast cancer by H&amp;E, immunohistochemistry and TUNEL staining. Transcriptome analysis, bioinformatics analysis and molecular docking analysis were used to explore the mechanism of psoralidin and cisplatin in improving breast cancer. The results showed that psoralidin could synergistically enhance the inhibitory effect of cisplatin on the proliferation of 4T1 breast cancer cells, promote the apoptosis of 4T1 cells, increase DNA damage and ROS expression. It also inhibited the expression of breast cancer cell proliferation-related molecules and energy metabolism factors related to tumor cell growth. Psoralidin could also synergistically enhance its inhibitory effect on tumor growth in breast cancer mice. Further molecular docking analysis revealed that psoralidin enhanced the killing effect of cisplatin on tumor cells by binding to <i>Nr1i2</i>. These findings provide a clear scientific basis for the enhancement of anticancer sensitivity to cisplatin by psoralidin.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Psoralidin enhances the sensitivity of breast cancer to cisplatin by targeting Nr1i2

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Meigong Zhong,
  • Meimei Wu,
  • Ruizhen Chen,
  • Jiadi He,
  • Yulan Qiu,
  • Jing Huang,
  • Yanyang Mai,
  • Wenjie Lu,
  • Wanting Wu,
  • Mingzhu Zheng,
  • Xiaoxue Huang,
  • Jie Ling,
  • Liangliang Ren,
  • Minxian Li,
  • Peifeng Lin,
  • Minli Chen,
  • Qin Zhang,
  • KwanNin To,
  • Yu Wang,
  • Dong Ren,
  • Xingxing Chai,
  • Lili Wang,
  • Zhonglin Xue,
  • Xin Zhang

摘要

We evaluated the therapeutic effect of psoralidin combined with cisplatin in a mouse model of breast cancer by H&E, immunohistochemistry and TUNEL staining. Transcriptome analysis, bioinformatics analysis and molecular docking analysis were used to explore the mechanism of psoralidin and cisplatin in improving breast cancer. The results showed that psoralidin could synergistically enhance the inhibitory effect of cisplatin on the proliferation of 4T1 breast cancer cells, promote the apoptosis of 4T1 cells, increase DNA damage and ROS expression. It also inhibited the expression of breast cancer cell proliferation-related molecules and energy metabolism factors related to tumor cell growth. Psoralidin could also synergistically enhance its inhibitory effect on tumor growth in breast cancer mice. Further molecular docking analysis revealed that psoralidin enhanced the killing effect of cisplatin on tumor cells by binding to Nr1i2. These findings provide a clear scientific basis for the enhancement of anticancer sensitivity to cisplatin by psoralidin.